Erweiterte Suche

Mathieu Lamy bekleidet die Position des Chief Operating Officer & Executive Vice President bei Intact Financial Corp. Er ist außerdem Senior Vice President-Claims bei Claims At Intact Insurance. Zuvor war er Chief Information Officer & Senior Vice President für IntAct Labs LLC, Executive Vice President-Operations für AXA Life Insurance (Canada) und Executive Vice President von AXA Canada, Inc. Herr Lamy erhielt einen Bachelor-Abschluss von der Universit Laval.

Derzeit bekleidet Mathieu Vrijsen die Position des Aufsichtsratsvorsitzenden bei Casco Phil, des Aufsichtsratsvorsitzenden bei Broadview Holding BV und des Aufsichtsratsvorsitzenden bei Corbion NV. Herr Vrijsen ist auch im Vorstand der Swiss-American Chamber of Commerce, The European Association for Bioindustries, Desso BV und Joma Sport BVBA sowie Mitglied des Executive Committee des International Institute for Management Development. In seiner früheren Karriere hatte er die Position des Senior Vice President-Operations & Engineering bei E.I. du Pont de Nemours & Co.

Mr. Mathieu Bonnet is a Chairman at E6 SAS, a Chief Executive Officer & Director at Allego BV, a Chief Executive Officer & Director at Allego NV, a Chief Executive Officer at Allego BV (New) and a President at Spartan Acquisition Corp.
III.
He is on the Board of Directors at Allego BV and Allego NV.
Mr. Bonnet was previously employed as a Chief Executive Officer by Compagnie Nationale du Rhône.
He received his undergraduate degree from Ecole Polytechnique, a graduate degree from École Nationale Supérieure des Mines de Paris and a graduate degree from Université Catholique de Louvain.

Dr. Mathieu Simon ist Chairman bei Epsilen Bio SRL, Chairman bei Idorsia Ltd., unabhängiges Mitglied des Verwaltungsrats bei Asarina Pharma AB, unabhängiges Mitglied des Verwaltungsrats bei Vaximm AG, Chairman bei Idorsia Pharmaceuticals Ltd., Chief Executive Officer bei Cellectis Therapeutics und unabhängiges Mitglied des Verwaltungsrats bei LNC Therapeutics SA. Er ist Mitglied des Board of Directors bei Lysogene SA, Asarina Pharma AB, Affimed NV, Affimed GmbH, Vaximm AG, Messier Maris & Associs SCA und LNC Therapeutics SA. Dr. Simon war zuvor als EVP, Chief Operating & Medical Officer bei Cellectis SA, als Vice President-Marketing & Medical Affairs bei Wyeth Pharmaceuticals LLC, als Group VP-Marketing & Clinical Affairs bei Wyeth-Ayerst International, Inc., als Senior Vice President-Global Operations bei Pierre Fabre Mdicament SAS, als Managing Director & Head-Global Pharma bei Pierre Fabre SA und als Chairman & Chief Executive Officer bei Takara Bio Europe AB tätig. Außerdem war er Vorstandsmitglied bei Alliance for Regenerative Medicine, Ectycell SASU und Farmindustria.

Mathieu Bernard Streiff is the founder of American Healthcare Investors LLC, which was founded in 2011.
He held the title of General Counsel & Managing Director at the firm from 2011 to 2019.
Mr. Streiff's current jobs include being a Director at Hawkhill House Ltd.
since 2016, a Director at American Healthcare REIT, Inc. since 2015, a Director at GAHC3 U.K.
Senior Care Holding Ltd., a Director at Coniston Care Centre Ltd.
since 2016, a Director at Orchard St Albans Housing Portfolio Ltd.
since 2015, a Member of the New York State Bar Association, an Executive Vice President at Griffin-American Healthcare REIT Sub-Advisor, LLC since 2012, and an Executive Vice President at Griffin-American Healthcare REIT III Advisor LLC since 2012.
Mr. Streiff's former jobs include being a Director at Trilogy Investors LLC, Executive Vice President & General Counsel at Grubb & Ellis Co. from 2010 to 2011, Executive Vice President & General Counsel at Griffin-American Healthcare REIT II, Inc. from 2012 to 2014, Executive Vice President & General Counsel at Griffin-American Healthcare REIT III, Inc. from 2013 to 2021, an Associate at Latham & Watkins LLP from 2002 to 2006, Secretary, Executive VP & General Counsel at Grubb & Ellis Realty Investors LLC in 2011, and Executive Vice President at Griffin American Healthcare Reit Advisor LLC from 2011 to 2014.
Mr. Streiff's education includes an undergraduate degree from the University of California, Berkeley and a graduate degree from Columbia Law School.

Herr Mathieu O. Floreani ist Vorstandsvorsitzender & CEO der Synlab AG, Co-Geschäftsführer der LS Medizin Service GmbH, Group Chief Executive Officer der SYNLAB International GmbH und Co-Geschäftsführer des Medizinischen Versorgungszentrums SYNLAB Leverkusen GmbH. Er ist Mitglied des Verwaltungsrats von Synlab Diagnsticos Globales SA, ALcontrol Group Ltd. und Labco UK Group Ltd. sowie von SYNLAB Ltd. Herr Floreani war zuvor als President, Chief Executive Officer & Director bei DHL Global Forwarding North America und als Managing Director bei SYNLAB Medizinisches Versorgungszentrum Stuttgart GmbH tätig.

Damien Lamy has worked as a Director at Euro Heat Pipes SA since 2008 and is currently employed there.
He is also a Director at KapCare SA, where he currently works.

Olivier Lamy is currently a Director at Pobi Industrie SA, Pobi Charpentes SA, Perform Habitat SAS, La Barrade SNC, and AST Services SAS.
He previously worked as a Director-Administrative & Finance at A.S.T.
Groupe SA from 2013 to 2016 and as a Senior Manager at Arthur Andersen & Cia from 2001 to 2002.
Mr. Lamy obtained his undergraduate degree from ESCP Europe Campus Paris in 1998 and Burgundy School of Business in 1998.

Donzé Aurélia Lamy worked as a Portfolio Manager at Edmond de Rothschild Asset Management (Suisse) SA from 2009 to 2015.

Mr. Arnaud-Guilhem Lamy is a Head of Euro Aggregate Bond Management Strategies at BNP Paribas Asset Management Europe SAS.
He is responsible for euro-aggregate's bond management strategies and is also an expert in socially responsible investment (SRI) for bond management.
Prior to joining BNP Paribas Asset Management in 2010, he was Eurobond Portfolio Manager at Fortis Investments in London (2007-2010), responsible for ABS and covered bonds.
He was a credit analyst at Société Générale Asset Management (2005-2007), after starting his career at Crédit Foncier de France in 2001 as a securitisation specialist.
He graduated in Finance and Economics from the Ecole Nationale de la Statistique et de l'Administration Economique (ENSAE, France, 2001).
He also holds a Master's degree in Applied Mathematics from Dauphine University (Paris, France, 1999).

Dr. Francis M.
Lamy is Chief Technology Officer at XR Ventures LLC.
Dr. Francis Lamy is Chief Technology Officer at XR Ventures LLC and Chief Technology Officer X-Rite.
Prior to joining XR Venture, he served as Executive Vice President and Chief Technology Officer for GretagMacbeth AG (Amazys Holding AG) from 2002-2006.
Prior to GretagMacbeth in 1999,he was the founder and president of Dalim, a workflow software company for the graphic arts markets, which he conducted from inception to world scale deployment.
Dr. Lamy holds a PhD in physics from the University Of Strasbourg, France.
Earlier in his career, in his post-doc days, he was assistant professor of Solid State Physics at the University of Strasbourg, and consultant to the French Ministry of Industry in innovation matters.

Caroline Lamy is currently working as the Co-Head of Equity Management at Crédit Mutuel Asset Management SA since 2021.
Previously, she worked as an Analyst at ING Belgium SA (France) in 2001.

Tristan Lamy currently works as the Chief Executive Officer and Director at Alenis SA.

Marc Lamy has held positions as an Independent Non-Executive Director at Alliances Developpement Immobilier SA and as a Founding Member at Institut Français Des Administrateurs.

Thomas Lamy is the founder of Biosynex SA, founded in 2005, where he holds the title of Director & Vice President.
He was also the founder of Dectra Pharm SAS, founded in 2005, where he held the title of Chief Executive Officer.
Additionally, he is the founder of All.
Diag SAS, founded in 1993, where he held the title of Chairman & Managing Director until 2015.
Dr. Lamy's current job(s) include being the Chief Executive Officer & Director at Biosynex Swiss SA, Chief Executive Officer & Director at Biosynex Premier SA, Chairman at A.J.T.
Financière SAS, and Sales Manager at PBS Orgenics.
Dr. Lamy's former job(s) include being a Director at Theradiag SA in 2022.
Dr. Lamy's education history includes an MBA from École des Hautes Études Commerciales de Paris and a doctorate from Institut National Polytechnique de Lorraine, conferred in 1986.

Christophe Lamy has been the General Manager at Envea SA since 2001.

Tiphanie Lamy is currently the Deputy Managing Director at FLCP & Associés SASU and FLCP & Associes Invest SAS.
She is also a Member-Supervisory Board at Focus Entertainment SA. Previously, she worked as a Director at Tuvalu Media Netherlands BV.

Esdra Lamy currently works at Airline Passenger Experience Association, Inc., as Director.

Emilie Lamy has worked as a Director at Prestige Motor Holdings SA since 2015.

Isabelle Lamy worked as a Secretary & Vice President-Legal Affairs at Emergia, Inc. from 2020 to 2022.

Sebastien Lamy is currently the Managing Director at Keppel Technology & Innovation Pte Ltd.
Prior to this, he worked as the Director-Group Strategy & Development at Keppel Ltd.
and as a Director at M1 Ltd.

Laurence Lamy currently works as a Manager of Corporate Communications at Mersen SA.

Yasemin Lamy joined British International Investment as Deputy CIO in August 2018.
She is responsible for the Catalyst Strategies, a portfolio aimed at transformational, system-level impact and innovation across its target geographies of Africa and South Asia.
Prior to British International Investment, she spent three years building two new portfolios for Omidyar Network: one portfolio to develop empowering digital identity technologies and one portfolio to establish a trendspotting capability.
Previously, she worked across several different roles within capital markets at J.P.
Morgan, starting out in fund-linked derivatives and then as a credit derivatives analyst, before building and leading the impact investment platform for the firm.
Yasemin has published widely and provided expert advice to the OECD, World Economic Forum and others.
She holds a Masters in Financial Mathematics from King’s College, London and a Bachelor in Mathematics and Philosophy from the University of Pennsylvania.

Pascal Lamy is currently the Director at Thomson Reuters Founders Share Co., Ltd., the Director at Centre on Regulation in Europe, a Professor at China Europe International Business School, and the President-Emeritus at Jacques Delors Institute.
He was formerly the Director General at the World Trade Organization.

Marc Lamy is currently a Director at Devolutions, Inc. He previously held positions as President, CEO, CFO & Director at Mindready Solutions, Inc., Director at LYRtech, Inc., Director at Accovia, Inc., Director at 9070-9759 Québec, Inc., Principal at Deloitte & Touche LLP, Chief Financial Officer at iBwave Solutions, Inc., and Chief Financial Officer at CrowdCare Corp.
He received both undergraduate and graduate degrees from the University of Montréal.

Maxim Saint-Amant Lamy worked as the Chief Compliance Officer & Operations Manager at Nymbus Capital, Inc. from 2019 to 2020.
He received his undergraduate and graduate degrees from HEC Montréal.

Daniel Lamy currently works at JPMorgan Securities Plc, as Strategist from 2004.

Mr. Gérard Lamy is a Director-Research at Wendel SA and a Member at The French Society of Financial Analysts.
He received his undergraduate degree from École des Hautes Études Commerciales de Paris.

Jean-Lucien Lamy is currently the Chief Executive Officer at FCI USA LLC.
Prior to this, he worked as a Director at Aliaxis SA.

Kenneth S.
Lamy is the founder of The Lamy Group Ltd.
He is currently working as a Director at the National Association of Real Estate Cos.

Julian Lamy was the founder of Watt-Learn, Inc. and held the title of Director.